{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:05:10Z","timestamp":1787843110980,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.atherosclerosis.2013.12.003","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T01:30:20Z","timestamp":1389144620000},"page":"707-712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial"],"prefix":"10.1016","volume":"233","author":[{"given":"Shui-ping","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-lian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-quan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib1","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib2","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib4","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ahj.2009.07.030","article-title":"Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study","volume":"158","author":"Zhao","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib7","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(95)90926-5","article-title":"Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0735-1097(98)00522-1","article-title":"Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. Cholesterol and recurrent events","volume":"33","author":"Pfeffer","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib11","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jacc.2008.05.046","article-title":"Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy. A PROVE IT\u2013TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy\u2013Thrombolysis In Myocardial Infarction 22) analysis","volume":"52","author":"Giraldez","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/clc.20984","article-title":"Threshold level of low-density lipoprotein cholesterol for the short-term benefit of statin therapy in the acute phase of myocardial infarction","volume":"35","author":"Lee","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(94)90506-1","article-title":"Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group","volume":"344","author":"Sacks","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib14","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2008.02.056","article-title":"Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction","volume":"101","author":"Lu","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMsa050467","article-title":"Major causes of death among men and women in China","volume":"353","author":"He","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/CIRCULATIONAHA.111.065904","article-title":"Serum lipids and lipoproteins in Chinese men and women","volume":"125","author":"Yang","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2010.07.006","article-title":"Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes","volume":"152","author":"Colivicchi","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5694\/j.1326-5377.2011.tb03237.x","article-title":"Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000\u20132007","volume":"195","author":"Aliprandi-Costa","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib19","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/ije\/18.3_Supplement_1.S159","article-title":"CHD and its risk factors in the People's Republic of China","volume":"18","author":"Tao","year":"1989","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib20","first-page":"390","article-title":"Chinese guidelines on prevention and treatment of dyslipidemia in adults","volume":"35","author":"Joint Committee for Developing Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults","year":"2007","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1253\/circj.70.1624","article-title":"Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design","volume":"70","author":"Miyauchi","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacc.2007.02.073","article-title":"Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials","volume":"50","author":"Alsheikh-Ali","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.12.003_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2005.05.086","article-title":"The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes","volume":"4","author":"Ray","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013007569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013007569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:39:05Z","timestamp":1758155945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915013007569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0021915013007569"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.003","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}